Literature DB >> 10334262

Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

J Ariza, M Pujol, J Cabo, C Peña, N Fernández, J Liñares, J Ayats, F Gudiol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10334262     DOI： 10.1016/s0140-6736(99)01017-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  44 in total

1.  Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital.

Authors:  A Marchese; G Balistreri; E Tonoli; E A Debbia; G C Schito
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.

Authors:  Y Ike; Y Arakawa; X Ma; K Tatewaki; M Nagasawa; H Tomita; K Tanimoto; S Fujimoto
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

3.  Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.

Authors:  Sebastian J van Hal; Michael C Wehrhahn; Thelma Barbagiannakos; Joanne Mercer; Dehua Chen; David L Paterson; Iain B Gosbell
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

4.  Linezolid in VAP by MRSA: a better choice?

Authors:  Malina Ioanas; Hartmut Lode
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

Review 5.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

6.  Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans.

Authors:  Susan L Fink; Richard A Martinello; Sheldon M Campbell; Thomas S Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 7.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 8.  Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.

Authors:  B P Howden; P B Ward; P D R Johnson; P G P Charles; M L Grayson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

9.  Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus.

Authors:  Mandy Wootton; T R Walsh; A P MacGowan
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

10.  VISA, hetero-VISA and VRSA: the end of the vancomycin era?

Authors:  John M Conly; B Lynn Johnston
Journal:  Can J Infect Dis       Date:  2002-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.